You are here

Online gene tests not as thorough as certified labs

Sites such as 23andMe promise a quick gene test but the results do need to be professionally validated

Dr Joshua Clayton sent his 23andMe genetic profile to another testing company, Promethease, and was erroneously told he had a mutation that can lead to fatal cancers at an early age. Many are uploading raw data created by genetictesting companies such as 23andMe and to other companies that are not certified to provide medical diagnoses.

New York

DR JOSHUA CLAYTON, a 29-year-old radiology resident at Baylor University Medical Center in Dallas, wanted to learn about his ancestry. So he sent a sample of his saliva to 23andMe, the genetic testing company.

His report was pretty mundane - no new revelations. But then he sent the profile created by 23andMe to a separate company called Promethease, which promises to do a more in-depth analysis for genetic mutations that cause disease.

The news was not good. Mr Clayton got back a report with a sinister red box at the top saying he had a mutation linked to Lynch syndrome, a frightening genetic disorder that leads to potentially deadly cancers at an early age. In an interview, he said he "knew, at least cursorily, that false positives were common with these tests", but "that didn't change the frightened feelings or concern, because I certainly couldn't blow it off".

After two weeks of panic and yet another genetic test at a company with expertise in medical diagnostics, he learnt the red box result was wrong. He simply didn't have the mutation.

Your feedback is important to us

Tell us what you think. Email us at

More Americans are embracing consumer genetic testing, but the Food and Drug Administration (FDA) limits what major firms like 23andMe or can say about a consumer's health.

So many people are taking an additional step: uploading all the raw data created by these companies to second companies for additional analysis. But these are not firms certified to provide medical diagnoses, nor are they sophisticated academic centres.

Companies such as Promethease warn customers not to regard their results as medical diagnoses. Mostly, they are comparing a consumer's raw data to gene variants reported to be linked to disease. But it's not at all clear that consumers understand how uncertain their results may be. There are no systematic studies of how often the direct-to-consumer results and third-party analyses are wrong. In one small study, Ambry Genetics - a lab certified to do medical testing - looked at 49 samples sent in by physicians whose patients had been told that they had disease-causing mutations by third-party interpreters.

Ambry found that 40 per cent were wrong. In addition, some genetic variations classified by second companies as threatening actually were benign. This tiny sample doesn't prove that the false-positive rate is 40 per cent. But patients such as Mr Clayton are not uncommon, genetic counsellors say. And they are increasingly worried about the flip side: false negatives that reassure consumers who actually should be worried.

Dr Judy Garber, director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute in Boston, said one of her patients was told by a consumer-testing company she had Li-Fraumeni Syndrome, which greatly raises the risk of a number of rare cancers. Further testing showed that that diagnosis was wrong. "It makes you worry about the people who don't come in," said Dr Garber.

"People think they are getting the same kind of genetic testing as they would get from a certified clinical laboratory," said Stephany Tandy-Connor, a genetic counsellor at Ambry. "Nothing could be further from the truth." Even some doctors are misled by the reports, she said. Of course, companies such as Ambry have an interest in making sure their business is not usurped by consumer-testing firms. But it's also true that the method used by consumer companies is different from certified clinical laboratories.

Consumer companies look for changes in tiny segments of genes, rather than examining the entire gene and looking for alterations. That is cheap but not comprehensive. And because they are not making medical diagnoses, these companies are not subject to the sort of quality controls as certified labs, which require extensive confirmation that results are free of errors. NYTIMES

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to